Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis blood pressure mystery: could a simple blood test hold clues?

NCT ID NCT07438925

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is investigating whether a substance called copeptin, which is a stable marker of the hormone vasopressin, is linked to blood pressure changes that happen during hemodialysis. Researchers will measure copeptin levels in routine blood samples from 71 adults on chronic dialysis and compare them with blood pressure readings taken before, during, and after sessions. The goal is to better understand how the body regulates fluid and blood pressure during dialysis, which could eventually help improve patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand blood pressure swings during dialysis, potentially leading to improved monitoring or treatment strategies.
What could go wrong
This is a small, observational study (71 people) that only looks for a link, not a treatment. The results may not apply to all dialysis patients or lead to any direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

71 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥18 years old) undergoing chronic hemodialysis for more than three months. All included patients were clinically stable, not hospitalized at the time of data collection, and received treatment within the ALTIR network (Association Lorraine pour le Traitement de l'Insuffisance Rénale). Data were obtained from three hemodialysis centers: Nancy-Brabois, Champelle, and Épinal.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years old). * Undergoing chronic hemodialysis treatment \> 3 months. * Availability of routine predialysis blood samples for copeptin and biochemical measurements. * Availability of blood pressure recordings before, during, and after hemodialysis sessions. No exclusion criteria if inclusion criteria is filled

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodialysis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes insipidus end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodialysis

Contacts and locations

Locations

  • CHRU de Nancy

    Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.